查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1434700

抗糖尿病药物市场：按类型、疾病、患者分类 - 全球预测 2024-2030

Antidiabetic Drugs Market by Type (Alpha-Glucosidase Inhibitors, Biguanides, DPP-IV (Dipeptidyl Peptidase) Inhibitors), Disease (Diabetes Mellitus Type 1, Diabetes Mellitus Type 2), Patient - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年抗糖尿病药物市场规模为469.3亿美元，预计2024年将达514.2亿美元，2030年将达923.2亿美元，复合年增长率为10.14%。

全球抗糖尿病药物市场

主要市场统计
基准年[2023] 469.3亿美元
预测年份 [2024] 514.2亿美元
预测年份 [2030] 923.2亿美元
复合年增长率（%） 10.14%
抗糖尿病药物市场-IMG1

FPNV定位矩阵

FPNV定位矩阵对于评估抗糖尿病药物市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对抗糖尿病药物市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场并分析其在成熟细分市场的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-抗糖尿病药物市场规模及预测是多少？

2-抗糖尿病药物市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些？

3-抗糖尿病药物市场的技术趋势和法律规范是什么？

4-抗糖尿病市场主要供应商的市场占有率是多少？

5-进入抗糖尿病药物市场合适的型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 糖尿病盛行率上升，肥胖人口增加
      • 提高病人和医护人员对糖尿病管理重要性的认识
      • 支持糖尿病意识和治疗的措施和计划
    • 抑制因素
      • 与抗糖尿病药物相关的不良反应
    • 机会
      • 持续研发抗糖尿病新药
      • 政府和私人公司合作提供廉价药品
    • 任务
      • 抗糖尿病药物核准的严格监管要求
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章抗糖尿病药物市场：依类型

  • α-Glucosidase酶抑制剂
  • 双胍类
  • DPP-IV（Dipeptidyl Peptidase）抑制剂
  • GLP-1（类升糖素胜肽）促效剂
  • 胰岛素
    • 中效胰岛素
    • 长效类似物
    • 预混合料胰岛素
    • 快速反应模拟
    • 短效类似物
  • Meglitinides
  • SGLT-II（钠葡萄糖转运蛋白）​​抑制剂
  • 磺酰尿素类
  • 胰岛素增敏剂

第七章 抗糖尿病药物市场：依疾病分类

  • 1型糖尿病
  • 2型糖尿病

第八章按患者分類的抗糖尿病药物市场

  • 成人用
  • 对于老年人
  • 儿童

第九章北美和南美抗糖尿病药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太抗糖尿病市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲抗糖尿病药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析

第13章竞争产品组合

  • 主要公司简介
    • Abbott Laboratories
    • Alkem Laboratories Ltd.
    • Aristo Pharmaceuticals Pvt. Ltd.
    • Astellas Pharma Inc.
    • AstraZeneca PLC
    • Biocon Limited
    • Boehringer Ingelheim International GmbH
    • Cadila Pharmaceuticals Limited
    • Cipla Limited
    • Dr. Reddy's Laboratories
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline PLC
    • Glenmark Pharmaceuticals Ltd.
    • Halozyme Therapeutics, Inc.
    • Johnson & Johnson Services, Inc.
    • Mankind Pharma Ltd.
    • Merck KGaA
    • Novo Nordisk A/S
    • Oramed Pharmaceuticals Inc.
    • Pfizer Inc.
    • PHC Holdings Corporation
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • 主要产品系列

第十四章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-437896AA367B

[190 Pages Report] The Antidiabetic Drugs Market size was estimated at USD 46.93 billion in 2023 and expected to reach USD 51.42 billion in 2024, at a CAGR 10.14% to reach USD 92.32 billion by 2030.

Global Antidiabetic Drugs Market

KEY MARKET STATISTICS
Base Year [2023] USD 46.93 billion
Estimated Year [2024] USD 51.42 billion
Forecast Year [2030] USD 92.32 billion
CAGR (%) 10.14%
Antidiabetic Drugs Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antidiabetic Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antidiabetic Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antidiabetic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories Ltd., Aristo Pharmaceuticals Pvt. Ltd., Astellas Pharma Inc., AstraZeneca PLC, Biocon Limited, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited, Cipla Limited, Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Halozyme Therapeutics, Inc., Johnson & Johnson Services, Inc., Mankind Pharma Ltd., Merck KGaA, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., PHC Holdings Corporation, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Tonghua Dongbao Pharmaceutical Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Antidiabetic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Alpha-Glucosidase Inhibitors
    • Biguanides
    • DPP-IV (Dipeptidyl Peptidase) Inhibitors
    • GLP-1 (Glucagon-like Peptide) Agonists
    • Insulin
      • Intermediate-Acting Insulin
      • Long-Acting Analog
      • Premixed Insulin
      • Rapid-Acting Analog
      • Short-Acting Analog
    • Meglitinides
    • SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
    • Sulphonylureas
    • Thiazolidinedione
  • Disease
    • Diabetes Mellitus Type 1
    • Diabetes Mellitus Type 2
  • Patient
    • Adult
    • Geriatric
    • Pediatric
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antidiabetic Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antidiabetic Drugs Market?

3. What are the technology trends and regulatory frameworks in the Antidiabetic Drugs Market?

4. What is the market share of the leading vendors in the Antidiabetic Drugs Market?

5. Which modes and strategic moves are suitable for entering the Antidiabetic Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Antidiabetic Drugs Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of diabetes and increasing obesity among people
      • 5.1.1.2. Growing awareness among patients and healthcare professionals regarding the importance of diabetes management
      • 5.1.1.3. Initiatives and programs supporting diabetes awareness & treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse effects associated with antidiabetic drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development for new antidiabetic drugs
      • 5.1.3.2. Governments and private companies collaborations to supply inexpensive drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements for the approval of antidiabetic drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Antidiabetic Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. Alpha-Glucosidase Inhibitors
  • 6.3. Biguanides
  • 6.4. DPP-IV (Dipeptidyl Peptidase) Inhibitors
  • 6.5. GLP-1 (Glucagon-like Peptide) Agonists
  • 6.6. Insulin
    • 6.7.1. Intermediate-Acting Insulin
    • 6.7.2. Long-Acting Analog
    • 6.7.3. Premixed Insulin
    • 6.7.4. Rapid-Acting Analog
    • 6.7.5. Short-Acting Analog
  • 6.7. Meglitinides
  • 6.8. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
  • 6.9. Sulphonylureas
  • 6.10. Thiazolidinedione

7. Antidiabetic Drugs Market, by Disease

  • 7.1. Introduction
  • 7.2. Diabetes Mellitus Type 1
  • 7.3. Diabetes Mellitus Type 2

8. Antidiabetic Drugs Market, by Patient

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Geriatric
  • 8.4. Pediatric

9. Americas Antidiabetic Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antidiabetic Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antidiabetic Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abbott Laboratories
    • 13.1.2. Alkem Laboratories Ltd.
    • 13.1.3. Aristo Pharmaceuticals Pvt. Ltd.
    • 13.1.4. Astellas Pharma Inc.
    • 13.1.5. AstraZeneca PLC
    • 13.1.6. Biocon Limited
    • 13.1.7. Boehringer Ingelheim International GmbH
    • 13.1.8. Cadila Pharmaceuticals Limited
    • 13.1.9. Cipla Limited
    • 13.1.10. Dr. Reddy's Laboratories
    • 13.1.11. Eli Lilly and Company
    • 13.1.12. F. Hoffmann-La Roche Ltd.
    • 13.1.13. GlaxoSmithKline PLC
    • 13.1.14. Glenmark Pharmaceuticals Ltd.
    • 13.1.15. Halozyme Therapeutics, Inc.
    • 13.1.16. Johnson & Johnson Services, Inc.
    • 13.1.17. Mankind Pharma Ltd.
    • 13.1.18. Merck KGaA
    • 13.1.19. Novo Nordisk A/S
    • 13.1.20. Oramed Pharmaceuticals Inc.
    • 13.1.21. Pfizer Inc.
    • 13.1.22. PHC Holdings Corporation
    • 13.1.23. Sanofi S.A.
    • 13.1.24. Takeda Pharmaceutical Company Limited
    • 13.1.25. Teva Pharmaceutical Industries Ltd.
    • 13.1.26. Tonghua Dongbao Pharmaceutical Co., Ltd.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ANTIDIABETIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIDIABETIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTIDIABETIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIDIABETIC DRUGS MARKET DYNAMICS
  • FIGURE 7. ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 10. ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2023 VS 2030 (%)
  • FIGURE 12. ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ANTIDIABETIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ANTIDIABETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTIDIABETIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTIDIABETIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIDIABETIC DRUGS MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTIDIABETIC DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTIDIABETIC DRUGS MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTIDIABETIC DRUGS MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 12. ANTIDIABETIC DRUGS MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTIDIABETIC DRUGS MARKET SIZE, BY LONG-ACTING ANALOG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTIDIABETIC DRUGS MARKET SIZE, BY PREMIXED INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTIDIABETIC DRUGS MARKET SIZE, BY RAPID-ACTING ANALOG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTIDIABETIC DRUGS MARKET SIZE, BY SHORT-ACTING ANALOG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTIDIABETIC DRUGS MARKET SIZE, BY MEGLITINIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTIDIABETIC DRUGS MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ANTIDIABETIC DRUGS MARKET SIZE, BY SULPHONYLUREAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTIDIABETIC DRUGS MARKET SIZE, BY THIAZOLIDINEDIONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 22. ANTIDIABETIC DRUGS MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ANTIDIABETIC DRUGS MARKET SIZE, BY DIABETES MELLITUS TYPE 2, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 25. ANTIDIABETIC DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. ANTIDIABETIC DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. ANTIDIABETIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 196. ANTIDIABETIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 197. ANTIDIABETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 198. ANTIDIABETIC DRUGS MARKET LICENSE & PRICING